Immunoglobulin A nephropathy (IgAN), considered the most prevalent form of primary glomerular disease worldwide, is characterized by the deposition of IgA in the mesangial area of the glomeruli and exhibits substantial clinicopathological heterogeneity [1]. Presently, the primary therapeutic approaches for IgAN patients involve supportive care, mainly included Angiotensin-Converting Enzyme Inhibitors (ACEI) or Angiotensin II Receptor Blockers (ARB), along with other symptomatic treatments, glucocorticoid therapy, and immunosuppressive therapy [2].
